Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 4.25 is in line with its 5-year average of 4.22, near the low end of its 5-year range (1.67–15.85).
As of the fiscal period ended Tuesday, June 30, 2026. 42.33% above its 12-month average of 2.99.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.25.
QUICK RATIO (ACID-TEST)
4.25
QUICK RATIO (ACID-TEST) AVG TTM
2.99
QUICK RATIO (ACID-TEST) AVG 3Y
2.82
QUICK RATIO (ACID-TEST) AVG 5Y
4.22
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+42.33%
CURRENT VS 3Y AVG
+51.00%
CURRENT VS 5Y AVG
+0.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+26.98%
vs the sector median at left
Xilio Therapeutics, Inc.
Market Cap
$60.89M
Quick Ratio (Acid-Test)
4.25
TTM Avg
2.99
3Y Avg
2.82
5Y Avg
4.22
Market Cap
$60.68M
Quick Ratio (Acid-Test)
10.98
TTM Avg
17.43
3Y Avg
9.10
5Y Avg
12.08
Market Cap
$61.67M
Quick Ratio (Acid-Test)
3.15
TTM Avg
4.21
3Y Avg
4.66
5Y Avg
4.26
Market Cap
$60.02M
Quick Ratio (Acid-Test)
1.35
TTM Avg
1.97
3Y Avg
5.50
5Y Avg
8.52
Market Cap
$59.78M
Quick Ratio (Acid-Test)
6.71
TTM Avg
8.38
3Y Avg
9.61
5Y Avg
10.03
Market Cap
$59.05M
Quick Ratio (Acid-Test)
2.37
TTM Avg
7.60
3Y Avg
7.51
5Y Avg
12.19
Market Cap
$62.85M
Quick Ratio (Acid-Test)
9.90
TTM Avg
11.46
3Y Avg
13.71
5Y Avg
15.39
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $60.89M | 4.25 | 2.99 | 2.82 | 4.22 |
| Kalaris Therapeutics Inc (KLRS)vs › | $60.68M | 10.98 | 17.43 | 9.10 | 12.08 |
| Fractyl Health, Inc. (GUTS)vs › | $61.67M | 3.15 | 4.21 | 4.66 | 4.26 |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | 1.35 | 1.97 | 5.50 | 8.52 |
| Adicet Bio, Inc. (ACET)vs › | $59.78M | 6.71 | 8.38 | 9.61 | 10.03 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.05M | 2.37 | 7.60 | 7.51 | 12.19 |
| Pliant Therapeutics, Inc. (PLRX)vs › | $62.85M | 9.90 | 11.46 | 13.71 | 15.39 |
| RenovoRx, Inc. (RNXT)vs › | $63.07M | 5.53 | 4.01 | 3.97 | 5.62 |
| Alps Group Inc (ALPS)vs › | $63.23M | 0.27 | 0.22 | 0.21 | 0.99 |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.41M | 1.51 | 1.60 | 1.72 | 2.07 |
Quick Ratio
4.25
Excludes inventory
Current Ratio
4.25
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 4.25 |
| 2026-03-31 | 3.59 |
| 2025-12-31 | 2.58 |
| 2025-09-30 | 2.20 |
| 2025-06-30 | 2.32 |
| 2025-03-31 | 1.96 |
| 2024-12-31 | 2.21 |
| 2024-09-30 | 1.67 |
| 2024-06-30 | 2.02 |
| 2024-03-31 | 2.19 |
| 2023-12-31 | 3.02 |
| 2023-09-30 | 3.81 |
| 2023-06-30 | 4.81 |
| 2023-03-31 | 5.99 |
| 2022-12-31 | 5.89 |
| 2022-09-30 | 8.45 |
| 2022-06-30 | 9.17 |
| 2022-03-31 | 14.81 |
| 2021-12-31 | 15.85 |
| 2021-09-30 | 8.20 |
| 2021-06-30 | 5.85 |
| 2021-03-31 | 8.75 |
| 2020-12-31 | 0.93 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
